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Abstract
Background: The objective of this pilot study was to identify biological, clinical or structural biomarkers of an
intra-articular hyaluronic acid injection efficacy (HYMOVIS®) for the design of a larger placebo-controlled clinical trial
studying the disease-modifying activity of this treatment.
Methods: Forty six patients with symptomatic knee Osteoarthritis (OA) were enrolled in this open-label,
prospective, multicenter, pilot study. Patients received two treatment cycles of intra-articular injections (3 mL) of
HYMOVIS® (8 mg/mL of hyaluronic acid hexadecylamide) at 6 months interval. Each treatment cycle involved two
intra-articular injections 1 week apart. All patients had Magnetic Resonance Imaging (MRI) of the target knee at
baseline and 1 year, and blood samples to assess joint biomarkers. The primary outcome was the change in type II
collagen-specific biomarkers (Coll2–1, Coll2–1NO2 and CTX-II) after HYMOVIS® treatment versus baseline. Secondary
endpoints included levels changes in aggrecan chondroitin sulfate 846 epitope (CS-846), Cartilage Oligomeric
Matrix Protein (COMP), procollagen type II N-terminal propeptide (PIIANP), Matrix Metalloprotease (MMP)-3,
Myeloperoxidase (MPO) and Interleukin (IL)-6 serum biomarkers, the ratio Coll2–1/PIIANP, CTX-II/PIIANP, variation of
MRI cartilage volume, and Knee injury and Osteoarthritis Outcome Score (KOOS) index.
Results: Coll2–1 serum levels significantly increased overtime while Coll2–1NO2 levels were only increased at D360.
Serum PIIANP levels also progressively and significantly enhanced with time. In contrast, other serum biomarker
levels including CTX-II, CS-846, COMP, MMP-3, MPO or IL-6 did not change significantly overtime. Interestingly, the
ratios Coll2–1/PIIANP and CTX-II/PIIANP decreased, indicating a decrease of cartilage catabolism. Compared to
baseline value, MRI cartilage volume and thickness increased in lateral femoral and lateral trochlea compartments
and not in medial compartment. These results, in addition to an improvement of T2 mapping score suggest a
positive structural effect of the product. Interestingly, WORMS effusion score, an indicator of synovitis, significantly
decreased. Finally, global KOOS score and subscales significantly increased overtime while pain at rest, walking pain
and patients or investigators global assessment of disease activity decreased. The safety profile was favorable with a
low incidence of injection-site pain.
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Conclusion: HYMOVIS®, a well-tolerated intra-articular treatment, significantly enhanced type II collagen turnover as
suggested by the increase in Coll2–1 and PIIANP levels and cartilage volume observed by MRI in lateral knee
compartment. Importantly, this study provides critical information for the design of a larger phase III clinical trial
investigating Disease Modifying effect of HYMOVIS®.
Trial registration: http://www.isrctn.com/ISRCTN12227846 11/02/2015.
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Background
Osteoarthritis (OA) is a disorder involving movable joints
characterized by cartilage degradation initiated by micro-
and macro-injury, synovial membrane inflammation and
abnormal subchondral bone remodeling. The disease
manifests first as a molecular derangement followed by
anatomic, and/or physiologic derangements that can cul-
minate in illness [1]. The knee is the most affected joint
by OA. In United States, it has a high prevalence of 40%
for men and 47% for women [2].
Up to date, there is no curative treatment for knee OA
despite availability of a large number of therapeutic options,
including nonpharmacological, pharmacological and surgi-
cal therapies. The aim of the pharmacological treatment re-
mains symptomatic to relieve pain and restore function [3–
8]. The first-line pharmacological therapy is the use of anal-
gesics such as paracetamol (acetaminophen) up to 4 g per
day. However, paracetamol has a short-term analgesic effect
and some meta-analysis indicated the occurrence of adverse
events i.e. liver injury [9, 10]. The second line therapy is the
use of non-steroidal anti-inflammatory drugs (NSAIDs).
However, chronic use of NSAIDs can result in serious com-
plications e.g. gastrointestinal bleeding, renal failure, coron-
ary heart disease even at normal dosage [11–13].
Viscosupplementation is recommended in the manage-
ment of symptomatic knee OA, for appropriate patients, by
many scholarly societies of rheumatology and orthopaedics
[4, 14–16] sport medicine [17] and geriatrics [18], on the
basis of recent systematic reviews and metaanalyses [19–
25]. Even though the clinical efficacy is now proved, at least
in selected patients, the structure-modifying effect remains
to be demonstrated. Two recent studies have suggested that
repeat intra-articular (IA) injections of hyaluronic acid
(HA) may delay the time to prosthetic replacement [26,
27]. Total knee replacement (TKR) is a valuable surrogate
marker of severe OA and a possible endpoint for clinical
trials, but unfortunately, is neither a reliable marker of the
lack of treatment efficacy nor of the anatomical progression
of the disease. Indeed, TKR is highly dependent on intrinsic
problems such as access barriers due to geographical and fi-
nancial considerations, the availability of the resources for
TKR and in the willingness of patients to be operated [28].
Therefore, additionnal studies are required to demonstrate
the structure-modifying effect HA viscosupplmentation in
knee OA.
HYMOVIS® is a sterile, non-pyrogenic, viscoelastic
hydrogel for intra-articular injection. The principal com-
ponent is HYADD®, a novel linear (i.e., not cross-linked)
HA chemical derivative containing between 1250 to
1800 disaccharides with a molecular weight comprised
between 500 to 730 kDa, displaying unique rheological
properties. Indeed, the modification with hexadecyla-
mine creates a network stabilized by reversible hydro-
philic and hydrophobic interactions (not by rigid
covalent cross-links), conferring high viscoelasticity to
this HA derivative. Unlike rigid chemically cross-linked
HAs, the reversible interactions stabilizing the mobile
reticulum allow for a complete recovery of the 3D struc-
ture of the gel (and, therefore, of its elasticity) after
mechanical shocks [29]. Thus, hexadecylamine structure
improves shock absorbing function of synovial fluid, and
potentially protect cartilage and soft tissues against
mechanical injuries. These properties together with the
prolonged residence time (between 2 to 5 weeks in ro-
dents) in the articular joints enable HYMOVIS® to re-
lieve pain and to improve joint function with a short
treatment regimen. In a recent preclinical study [30],
HYMOVIS® has exhibited beneficial effects on both
chondrocyte and synovial fibroblast expression of cata-
bolic enzymes and inflammatory cytokines/mediator. Re-
cently, a retrospective study and one open-label study
have reported that two intra-articular injections of
HYMOVIS® 1 week apart reduced pain and improved
function for at least 1 year after the first injection in
knee OA patients [31, 32] and one single-center single-
blind prospective randomized clinical trial evidenced
that two injections 7 days apart of HYMOVIS® provided
better short-term (at 26 weeks but not 52 weeks) effects
on pain and function than two injections of methylpred-
nisolone acetate in patients with mild to moderate knee
osteoarthritis [33].
This pilot study aimed to explore the potential structure-
modifying effect of HYMOVIS® in patients suffering of knee
OA using a combination of scientifically sound, objective
measurements of clinical, biological and MRI-based im-
aging markers [34].
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Patients and methods
Study design
This was an open, multicenter, prospective study, asses-
sing the effectiveness of two treatment cycles of HYMO-
VIS® (FIDIA Farmaceutici, Via Ponte della Fabbrica, 3/A
35031 Abano Terme (Padova) Italy; 8 mg/ml of hyaluronic
acid partial hexadecylamide in 3ml sterile syringe
[CE0459]) at 6-month interval, each treatment cycle in-
volved 2 intra-articular injections given at 1-week interval
(Fig. 1). The study was conducted prospectively by 8 in-
vestigators (rheumatologists and rehabilitation medicine
physicians) located in Belgium (n = 4) and in France (n =
4) from public or academic hospitals between February
9th 2015 to June 6th 2017. The same injector had to per-
form all the injections of a patient to reach homogeneity.
This trial has been conducted according to the “Declar-
ation of Helsinki” and in compliance with Good Clinical
Practice (GCP) principles for Medical Devices (ISO14155:
2011). Centralized biomarker platform operated under
Good Clinical Laboratory Practice guidelines (GCLP/
WHO). In Belgium, the protocol has been submitted to
the central Ethic Committee (EC) from the University
Hospital of Liege and appropriate local ethical committee
on September 9th 2014 and approved by November 12th
2014 (B707201422130–2014/247). In France, the protocol
has been submitted to the Comité de Protection des Per-
sonnes Iles-de France IV and to the French competent au-
thorities (ANSM) as Biomedical Research on February
25th 2015. Approval has been obtained on April 10th
2015 (2015/11) and May 6th 2015(2015-A00370–49), re-
spectively. The study was conducted in strict accordance
with the declaration of Helsinki and GCP principles. Each
patient received and signed an informed consent.
Eligibility of patients
Eligible patients were men or women, aged between 40
and 80 years with a Body Mass Index (BMI) ≤ 40 kg/m2
suffering of unilateral symptomatic femorotibial knee
OA associated or not with femoropatellar knee OA
responding to clinical and radiological criteria of ACR
(American College of Rheumatology). OA must have
been symptomatic for more than 6months in the most
painful knee with a mean global pain at rest determined
on Visual Analog Scale (VAS) for the last 24 h over 40
mm (with a washout period for paracetamol and oral
NSAIDs depending on the half-life of the drug). Kellgren
and Lawrence (KL) score evidenced with X-rays over the
past 12 months must have been II or III. Patients signed
their informed consent after receiving comprehensive
information.
Exclusion criteria
The exclusion criteria were selected to avoid the presence
of a contraindication to treatment or diseases affecting
biomarkers clearance and to exclude the interference of
concomitant painful condition or therapies that may
modulate cartilage metabolism. They also considered con-
traindications to perform Magnetic Resonance Imaging
(MRI). Patients meeting to at least one of the criteria de-
tailed in Table 1 were not included in the study.
Prohibited/authorized treatments
Authorized treatments during the trial were paracetamol
only if needed at the maximal dose of 4 g per day and oral
NSAIDs only if paracetamol at 4 g per day was not suffi-
cient and only for a period as shorter as possible. Symp-
tomatic Slow Acting Drugs in OA (SYSADOA) including
chondroitin, diacerein, glucosamine, soy and avocado
unsaponifiables were also authorized in stable dosage and
only if began and stable from 3months before first injec-
tion. Similarly, non-pharmacologic modalities (including
physical therapy) for the lower extremities were accepted
only if it began at least 1 month before first injection and
was stable during the trial. Usual treatments taken by the
subject in other no OA-related diseases were kept as con-
stant as possible during the trial. Bisphosphonates in stable
dosage and only if began for more than 14 days before first
injection was also authorized. Prohibited treatments during
the study were corticosteroids or hyaluronan injection in
any joint, oral corticotherapy, curcumin based treatment
(e.g. Flexofytol®), analgesics except paracetamol, NSAIDs at
the exception of oral form, anticoagulant (coumarinic
Fig. 1 Study design. KOOS = Knee Injury and Osteoarthritis Outcome Score; VAS = Visual Analog Scale; MRI = Magnetic Resonnance Imaging
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compound) and heparin and osteoporosis-related treat-
ments based on strontium ranelate, selective estrogen-
receptor modulator (SERM) and parathormone (PTH).
Outcomes measures
Demographic data, medical history, eligibility criteria,
concomitant treatments were recorded at screening visit
scheduled 30 days (D30) before the first injection regi-
men. MRI acquisition was performed in the month pre-
ceeding the first injection, but also 6 months (D180) and
12months (D360) after this injection. Images were
transferred to the centralized imaging platform (ARTIA-
LIS SA, Liège, Belgium) for quality check and reading.
The semi-quantitative Whole-Organ Magnetic Reson-
ance Imaging Score (WORMS) and its 14 features (ar-
ticular cartilage integrity, subarticular bone marrow
abnormality, subarticular cysts, subarticular bone attri-
tion, marginal osteophytes, medial and lateral meniscal
integrity, anterior and posterior cruciate ligament integ-
rity, medial and lateral collateral ligament integrity,
synovitis/effusion, intraarticular loose bodies, and peri-
articular cysts/bursitis) were evaluated in 14 subregions
(patella/femur/tibia) of the knee [35]. T2 relaxation time
were evaluated in patella, femur and tibia subregions
and in the following cartilage sub-regions medial tibia,
medial weight bearing femur, medial trochlea, lateral
tibia, lateral weight bearing femur and lateral trochlea.
Cartilage volume (mm3), thickness (mm), and bone
curvature were reported for femur, tibia, patella, and for
the following cartilage subregions: medial tibia, medial
weight bearing femur, medial trochlea, lateral tibia, lat-
eral weight bearing femur and lateral trochlea.
The Knee Injury and Osteoarthritis Outcome Score
(KOOS) and its subscale scores using a self-administered
questionnaire, the mean knee pain over the last 24 h at
rest and while walking using a VAS, the global assess-
ment of disease activity (by patient and by investigator)
using a VAS, responder rate to treatment (following
OARSI OMERACT criteria), patient satisfaction by a
five-category scale (i.e. better, little better, same, little
lower or far lower), concomitant treatments, adverse
events and drop-off were recorded at each visit. Adverse
events were recorded immediately after the injections
and during the follow-up visits.
Serum (s) and urine (u) were collected at D0, D30,
D90, D180, D210 and D360 for each subject by the clin-
ical laboratory of each investigation site and shipped to
the centralized biomarker platform (Artialis SA, Liège,
Belgium) for biomarker testing at appropriate frequency.
Samples have been assayed in pooled test series using vali-
dated immunoassay assays and according to written proce-
dures provided by the manufacturer. sColl2–1 (Artialis SA,
Liège Belgium), sColl2–1NO2 (Artialis SA, Liège Belgium),
uCTXII (Immunodiagnostic Systems Limited (IDS), Boldon,
Table 1 Exclusion criteria
Related to the OA pathology
• Bilateral (except asymptomatic and grade I) OA of the knee
• Radiological K&L grade I or IV
• Chondromatosis or villonodular synovitis of the knee
• Recent trauma (< 1month) of the knee responsible of the
symptomatic knee
• Acute inflammatory osteoarthritis (Kofus ≥7)
• Articular disease resulting from articular dysplasia, aseptic
osteonecrosis, acromegaly, Paget’s disease, hemophilia,
hemochromatosis….
• Inflammatory disease i.e. rheumatoid arthritis, gout and infectious
arthritis, acute calcium pyrophosphate arthritis
• Pathologies interfering with the evaluation of OA (radiculalgia in the
lower limbs, arteritis…..)
• Presence of another joint (other than the target knee) affected by OA
(confirmed in radiographs and symptomatic)
Related to treatments
• Corticosteroids injection in the target knee in the last month before
first injection
• Hyaluronan injection in the target knee in the last 6 months before first
injection
• Arthroscopy and surgery in the target knee in the last 6 months before
first injection
• Oral corticotherapy ≥5 mg/day (in Prednisone equivalent) in the last 3
months before first injection
• OA treatments based on curcuma extract (e.g. FLEXOFYTOL) in the last
3 months before first injection
• Change in the dosage of symptomatic slow-acting drugs (SYSAD) i.e.
chondroitin, glucosamine, diacerein or avocado-soya unsaponifiables in
the last 3 months before first injection
• Paracetamol and oral NSAIDs before inclusion and follow-up visits
(washout period depending on the half-life of the drug).
• Osteoporosis-related treatments based on strontium ranelate, selective
estrogen-receptor modulator (SERM) and parathormone (PTH) in the
last 12 months before first injection
• An anticipated need for any forbidden OA treatments during the trial
• Contraindications to HYMOVIS®: hypersensitivity to the product
components and infections or skin diseases in the area of the injection
site
• Non-pharmacologic therapy (including physical therapy) for the lower
extremities initiated in the month before first injection
• Anticoagulant (coumarinic compound) and heparin
Related to associated diseases
• Severe diseases (liver or renal failure, lung/heart disease, tumor, HIV….)
• Allergy or contra-indication to hyaluronan and constituents
• Severe alteration of mobility unabling functional evaluation
• High risk of hemorrhage and risk of infection at the site of injection
• Anticipated need for any surgical or other invasive procedure during
the trial including prosthesis in the target knee
Related to patients
• Participation to a therapeutic clinical trial in the last 3 months before
first injection
• Under guardianship or judicial protection
• Pregnancy, breastfeeding, planned conception, premenopausal women
without contraception, tubal ligation or hysterectomy
Related to MRI counter-indication
• Patient with a pacemaker, an implantable defibrillator, neurosurgical
clips, a neurostimulator, cochlear implant, a stent from less than 3
weeks, an insulin pump
• Patient with a ferromagnetic splinter in the body, or having wire
sutures
• Serious mobility problem (Parkinson, tremors),
• Claustrophobia
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Tyne and Wear, UK), sCS-846 (IBEX, Montréal, Canada),
sCOMP (BioVendor, Brno, Czech Republic), sPIIANP
(Merck, Darmstadt, Germany), and sMMP-3, sMPO, sIL-6
(Bio-Techne, Abingdon, UK). CTX-II was normalized on
creatinine (Quidel Corporation, San Diego, USA).
Primary outcomes
This is a post-marketing study designed to explore the
effect of HYMOVIS on cartilage metabolism and to ex-
plore the potential of Coll2–1, Coll2–1NO2 and CTX-
II as companion biomarkers for the follow-up of pa-
tients treated with HYMOVIS. This was the reason for
which we have selected Coll2–1, Coll2–1NO2 and
CTX-II as primary end-points. The primary outcome
measures were the levels of sColl2–1, sColl2–1NO2
and uCTX-II biomarkers at baseline (D0) and at the
different time points.
Secondary outcomes
The secondary outcome measures were the levels of sCS-
846, sCOMP, sPIIANP, sMMP-3, sMPO and sIL-6 bio-
markers; the measure of MRI WORMS score, T2 relaxation
time (whole, top, middle and bottom layers), cartilage vol-
ume, thickness and curvature; function evaluated with
KOOS index, VAS for the mean knee pain over the last 24
h at rest and while walking, VAS for the global assessment
of disease activity (by patient and by investigator), re-
sponder rate to treatment (OARSI-OMERACTcriteria), ad-
verse events, drop-off and patient satisfaction scale.
Statistical analysis
Sample size
The sample size was calculated following recommenda-
tions and guidance on statistical principles for clinical tri-
als [36, 37], considering a minimal biomarker difference
between time points at least equal to the variability of the
Fig. 2 Patient disposition. FAS = Full Analysis Set; PP = Per Protocole
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assay (primary endpoint, s = θ = 10%). It was calculated to
estimate a sample size for a future trial studying the
disease-modifying effect of the product. Sample size was
calculated according to the paired t-test formula assuming
a type I error rate of 0.05 and an 80% power (type II error)
. The sample size varied according to the assumed correl-
ation (Corr) between the pre and post visits. The sample
was sized on the worst case (10% correlation). With 17
cases, the power was 90.5, 97.2 and 99.9% in case of
higher correlations, respectively 0.3, 0.5 and 0.7. Moreover,
the sample size was inflated according to the theoretical
responder rate (RR) determined from the literature [38]
(RR = 56.8%) and potential study drop-off (DO = 40%).
Therefore, a total number of 50 patients was planned to
be enrolled.
Analysis of the primary outcome
Analyses were performed using the Statistical Analysis
Software SAS (version 9.4, SAS Institute Inc., Cary, NC,
USA). First, baseline (D0) sColl2–1, sColl2–1 NO2 and
uCTX-II concentrations were compared with those ob-
tained at D30, D90, D180, D210 and D360 days by using
a paired t-test (or a Wilcoxon signed-rank test if the data
were deemed non-normal). Moreover, a repeated mea-
sures mixed model was applied using the change from
baseline in biomarker levels as the outcome variable,
visit as qualitative independent variable and baseline x
visit interaction as covariate. P-values of the fixed effects
and covariates have been presented and estimates at
each time point have been given with 95% confidence in-
tervals. Analyses were performed both in the Full Ana-
lysis Set (FAS) and Per-Protocol (PP) populations. Full
Analysis Set (FAS) corresponded to all subjects who re-
ceived at least one treatment cycle consisting of two in-
jections at 1 week interval. Per-Protocol Set (PP) were
all subjects who received all the injections and had no
major protocol deviations.
Analysis of the secondary outcomes
The secondary biomarkers endpoints were analyzed
using the same statistical methods that described for the
primary endpoints. The MRI endpoints (WORMS, T2
relaxation time, cartilage volume, thickness and curva-
ture) have been analyzed with the Paired t-test or Wil-
coxon signed-rank tests comparing the results observed
at D180 and D360 versus the baseline visit (D0). The
WORMS values have been analyzed by compartments
and using the total score. The T2 relaxation time have
been analyzed by layers and using the total score as well.
The KOOS (sub-score and total score) and VAS scales
have been analyzed using the same statistical methods
that biomarkers endpoints. The responder rate accord-
ing to the OARSI-OMERACT ratio was calculated at
each time point and all the analyses of biomarkers has
been repeated in subgroups of responders and non-
responders. Moreover, the level of biomarkers at each
assessment has been compared between responders and
non-responders with the T-test (or the Wilcox rank-sum
test if the data are deemed non-normal). Correlations
between variables (biological and/or MRI-based imaging
markers) has been obtained using the Spearman rank’s
correlation test. Patient’s satisfaction has been analyzed
using shift tables and the McNemar test. The analyses
have been performed in the FAS population. No formal
hypothesis testing of safety data (Adevrse Effect (AE)
and drop-off ) has been undertaken, but descriptive sta-
tistics have been performed. The Safety Analysis Set
(SAS) has been used when summarizing safety data.
Safety Set included all subjects who received at least




Fifty patients [39] were screened from which 46 entered
the Multicenter Osteoarthritis Knee Hyaluronic Acid
(MOKHA) Study. Forty-one (41; 89%) completed the
study and 5 (11%) discontinued: 4 for personal reasons
not related to the study and 1 for disease incompatible
with the pursuing of the study decided by the patient.
Eighteen (39.1%) patients out of 46 presented at least
one major deviation. Major deviations were intake of
prohibited medication (n = 10; 21.7%), no respect of the
treatment regimen (n = 3; 6.5%), the presence of at least
one exclusion criteria (n = 2; 4.3%) or the non-respect of
delays between visits (n = 7; 15.2%). Forty-six patients re-
ceived at least one treatment injection (SAS), 46 patients
received at least one treatment cycle consisting of two
injections at on week intervals (FAS) and 28 patients re-
ceived a total dose of 4 injections without any major
protocol violations (PP) (Fig. 2).
Table 2 Demographic data and OA history of the FAS
population (N = 46)




BMI (Kg/m2; mean (SD)) 30.6 (5)




Radiological score (Kellgren &Lawrence)
Score II 63%
Score III 37%
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Table 3 levels (median (IQR)) of soluble biomarkers in the Full Analysis Set Population
D0 D30 D90 D180 D210 D360
sColl2–1(nM) n = 46; 498.66
(297.61;647.44)
n = 46; 578.30
(399.97;724.51)
n = 43; 634.46
(439.25;787.76)
n = 43; 635.01
(484.51;824.38)




Change from baseline n = 46; 20.84
(−42.75;132.08)
n = 43; 50.25
(−42.03;242.73)
n = 43; 149.62
(28.17;297.19)




P-value vs D0 0.098 0.021 < 0.001 0.010 < 0.001
sColl2-NO2(pg/ml) n = 30; 340.21
(266.24;425.99)
n = 36; 268.61
(206.13;370.75)
n = 34; 293.75
(233.64;464.92)
n = 34; 336.82
(265.68;450.43)
n = 29; 396.35
(284.85;598.79)
n = 31; 384.53
(303.84;663.99)
Change from baseline n = 30; −28.54
(−71.03;53.08)
n = 27; −17.33
(−64.21;67.82)
n = 26; 18.57
(−49.93;120.00)
n = 22; 29.31
(− 67.38;198.32)
n = 25; 69.75
(− 13.51;294.24)
P-value vs D0 0.243 0.907 0.225 0.272 0.027
uCTX-II (ug/mmol creatinine) n = 37; 0.012
(0.009;0.015)
n = 37; 0.012
(0.009;0.015)
n = 34; 0.010
(0.008;0.016)
n = 37; 0.012
(0.009;0.015)
n = 34; 0.011
(0.008;0.015)
n = 36; 0.012
(0.008;0.016)
Change from baseline n = 33; 0.001
(−0.002;0.003)
n = 31; 0.000
(−0.003;0.002)
n = 33; 0.000
(− 0.002;0.002)
n = 31; 0.000
(− 0.002;0.003)
n = 33; 0.000
(− 0.003;0.003)
P-value vs D0 0.733 0.924 0.882 0.924 0.910
sPIINP (ng/ml) n = 45; 599.50
(502.45; 812.42)
n = 42; 667.45
(519.13; 827.70)
n = 40; 708.90
(548.63; 873.46)
n = 41; 780.20
(572.88; 983.53)
n = 37; 858.79
(738.85;1061.52)
n = 37; 1057.41
(726.91;1268.47)
Change from baseline n = 41; 31.2
(−87.64;117.27)
n = 40; 74.82
(−83.03;193.95)
n = 41; 96.97
(5.27;298.16)
n = 37; 190.11
(138.91;319.81)
n = 37; 433.90
(136.71;573.78)
P-value vs D0 0.954 0.038 < 0.001 < 0.001 < 0.001
sColl2–1(nM)/sPIINP
(ng/ml)
n = 45; 0.72
(0.53; 0.96)
n = 42; 0.80
(0.56; 1.03)
n = 40; 0.69
(0.56; 1.05)
n = 41; 0.81
(0.62; 1.00)
n = 37; 0.69
(0.54;0.93)
n = 37; 0.56
(0.48;0.81)
Change from baseline n = 41; 0.04
(−0.11; 0.26)
n = 40; − 0.02
(− 0.18; 0.30)
n = 41; 0.04
(− 0.14; 0.36)
n = 37; − 0.04
(− 0.26; 0.22)
n = 37; − 0.11
(− 0.28; 0.00)
P-value vs D0 0.291 0.677 0.257 0.678 0.005
uCTX-II (ng/mmol creatinine)/
sPIINP (ng/ml)
n = 36; 0.019
(0.012; 0.027)
n = 33; 0.018
(0.012; 0.026)
n = 33; 0.015
(0.011; 0.022)
n = 36; 0.016
(0.011; 0.024)
n = 33; 0.014
(0.011; 0.020)
n = 31; 0.012
(0.008; 0.019)
Change from baseline n = 28; −0.001
(− 0.004; 0.003)
n = 30; − 0.004
(− 0.008; 0.002)
n = 32; − 0.003
(− 0.008; 0.001)
n = 30; − 0.004
(− 0.010; − 0.001)
n = 28; − 0.006
(− 0.013; − 0.001)
P-value vs D0 0.219 0.041 0.010 0.004 0.001
sCS-846 (ng/ml) n = 38; 153.03
(124.60;186.18)
n = 38; 141.94
(125.27;185.74)
n = 36; 150.27
(114.88;180.88)
n = 37; 163.23
(134.32;185.58)
n = 36; 153.50
(121.16;178.61)
n = 39; 157.41
(130.60;186.27)
Change from baseline n = 34; −6.35
(−19.86;12.92)
n = 32; −5.52
(−24.24;19.69)
n = 31; −1.54
(− 18.28;22.55)
n = 30; − 1.97
(− 19.82;20.00)
n = 33; 2.67
(− 17.60;19.17)
P-value vs D0 0.086 0.419 0.863 0.756 0.787
sCOMP (ng/ml) n = 46; 796.15
(615.97;1044.40)
n = 45; 823.23
(617.95;1032.53)
n = 43; 737.14
(602.20;982.47)
n = 43; 740.58
(626.94;968.86)
n = 39; 763.79
(573.95;991.30)
n = 42; 846.46
(613.54;1060.12)
Change from baseline n = 45; −14.69
(−94.76;118.464)
n = 43; −4.86
(− 164.98;89.46)
n = 43; −26.32
(− 116.87;79.57)
n = 39; −24.32
(− 98.96;108.31)
n = 42; 15.30
(− 123.31;109.46)
P-value vs D0 0.934 0.310 0.404 0.701 0.936
sMMP-3 (ng/ml) n = 46; 14.86
(11.99;20.90)
n = 46; 15.75
(12.48;23.64)
n = 43; 16.36
(13.71;22.17)
n = 42; 15.87
(12.05;21.91)
n = 38; 15.95
(12.54;22.27)
n = 42; 14.87
(11.03;19.16)
Change from baseline n = 46; 1.19
(−1.11;3.17)
n = 43; 1.61
(− 1.37;3.53)
n = 42; 0.62
(−2.64;3.33)
n = 38; 0.85
(− 1.81;2.68)
n = 42; −0.03
(−3.21;2.57)
P-value vs D0 0.138 0.041 0.726 0.420 0.792
sIL-6 (pg/ml) n = 46; 1.62
(1.23;2.16)
n = 45; 1.70
(1.35;2.63)
n = 41; 1.67
(1.29;2.61)
n = 42; 1.54
(1.20;2.33)
n = 37; 1.71
(1.21;2.73)
n = 42; 1.95
(1.35;2.86)
Change from baseline n = 45; 0.19
(−0.23;0.51)
n = 41; 0.04
(− 0.30;-0.61)
n = 42; 0.014
(− 0.23;0.49)
n = 37; 0.175
(− 0.28;0.44)
n = 42; 0.26
(− 0.31;1.04)
P-value vs D0 0.119 0.448 0.534 0.410 0.081
sMPO (ng/ml) n = 44; 176.08
(128.28;251.10)
n = 44; 189.13
(104.79;260.37)
n = 41; 182.85
(132.41;288.12)
n = 41; 184.19
(105.37;264.12)
n = 35; 158.36
(87.61;250.25)
n = 38; 168.92
(11.21;239.39)
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Patient characteristics
Patients were mainly women (67.4%) with a mean age of
61.4 (9.6) years and a BMI of 30.60 [5] kg/m2. Patients
were suffering from knee OA for a mean of 4.54 (5.9)
years. The most painful knee was the right knee for
67.4% of the patients. Sixty-three (63) percents had a KL
grading of II and 37% a KL of III (Table 2).
Primary efficacy outcomes
sColl2–1 showed a significant increase at D90 and over in
both FAS and PP population (Tables 3 and 4). sColl2–1
NO2 showed a significant increase only at D360 in the FAS
(Table 3), but not in the PP population (Table 4). At D360,
the effect size calculated on the FAS population was 0.47
(p = 0.022) for Coll2–1and 0.32 for Coll2–1NO2 (p = 0.048).
uCTX-II Biomarker did not show any significant change
over time in both FAS and PP population (Tables 3 and 4).
Secondary efficacy outcomes
Biological parameters
Among all biomarkers tested as secondary outcomes, only
sPIIANP levels significantly changed during the study (Ta-
bles 3 and 4). A significant increase of sPIIANP was ob-
served from D90 in the FAS population and from D180 in
the PP set. The other biomarkers did not vary overtime.
Further, the increase of PIIANP between D0 and D90
was significantly lower in OARSI-OMERAC responders
than in non-responders (responders 39.3157.43 (208–
84.65; 172.50) ng/ml vs non-responders 239.41258.27
(46.09182.03; 273.51) ng/ml; p = 0.008). No difference
was observed if we consider the variation of PIIANP be-
tween D0 and D360.
No significant differences at baseline or changes over
time were observed in sColl2-1, Coll2–1 N02 or CTX-II
levels between clinical responders and non-responders.
The ratios Coll2–1/PIIANP at D360 (p = 0.005) and CTX-
II/PIIANP from D90 to D360 (0.05 < p < 0.001) decreased,
indicating a decrease of cartilage catabolism. At D360, the
effect size calculated on the FAS population was 0.46 (p =
0.005) and 0.720 (p = 0.001) for the ratio Coll2–1/PIIANP
and CTX-II/PIIANP respectively.
MRI features
WORMS total score, that represents a summation of
grades for all of the knee features, showed a significant
(p = 0.037) increase at D360. WORMS total cartilage and
total cysts features were also significantly increased (cartil-
age: mean change (SD): 0.45 (1.21); p = 0.025); cysts: mean
change (SD): 0.23 (0.63), p = 0.047) at D360. Interestingly,
WORMS effusion score was significantly decreased at
D180 that was not maintained at D360. Other WORMS
total features or WORMS compartments were not signifi-
cantly modified over time (Table 5).
Mean T2 relaxation time (ms) was significantly de-
creased overtime in the femur compartment for 8 distinct
features (Table 6): femur whole layers (median change: −
0.537ms, p = 0.050 at D180 and − 1.595ms, p = 0.014 at
D360), femur middle layer (median change: − 0.596ms,
p = 0.03 at D180 and − 1.249ms, p = 0.008 at D360), femur
bottom layer (median change: − 2.051ms, p = 0.009 at
D360), lateral weight bearing femur whole (median
change: − 3.129ms, p = 0.011 at D180 and − 1.748ms, p =
0.032 at D360), lateral weight bearing femur middle (me-
dian change: − 1.075ms, p = 0.005 at D180 and − 1.264
ms, p = 0.045 at D360), lateral weight bearing femur bot-
tom (median change: − 1.599ms, p = 0.015 at D180). In
contrast, mean T2 relaxation time was not modified in the
medial compartment. Standard deviation of T2 relaxation
was significantly reduced in the femoral cartilage for the 5
following distinct features: femur bottom (median change:
− 0.944ms, p = 0.027 at D180), lateral weight bearing
femur bottom (median change: − 1.053ms, p = 0.005 at
D180), medial weight bearing femur middle (median
change: − 1.355ms, p = 0.037 at D180), medial weight
bearing femur bottom (median change: − 1.506ms, p =
0.010 at D180 and median change: − 2.298ms, p = 0.012
at D360). Similarly, at patella level, mean and SD of T2 re-
laxation time showed a significant decrease, the majority
being observed starting from D180, for 7 distinct features:
patella medial trochlea whole, patella medial trochlea top,
patella medial trochlea middle, patella medial trochlea
bottom, patella lateral trochlea whole, patella lateral troch-
lea middle, patella lateral trochlea bottom. No significant
changes were observed at the tibia level (Table 6).
Cartilage volume significantly increased at D360 in the
lateral weight bearing femur (median change = 66mm3,
p = 0.03) and the patella lateral trochlea (median
change = 77mm3, p = 0.028). No significant volume
change was observed in the other compartments.
Cartilage thickness significantly increased at D360 in
the lateral weight bearing femur (median change: 0.023
Table 3 levels (median (IQR)) of soluble biomarkers in the Full Analysis Set Population (Continued)
D0 D30 D90 D180 D210 D360
Change from baseline n = 43; −3.77
(−52.92;69.34)
n = 40; 1.32
(−45.19;75.32)
n = 39; 0.07
(−71.70;78.37)
n = 34; −24.03
(−64.88;39.60)
n = 36; − 11.28
(− 39.45;12.45)
P-value vs D0 0.767 0.412 0.816 0.183 0.202
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Table 4 levels (median (IQR)) of soluble biomarkers in the Per Protocol Population
D0 D30 D90 D180 D210 D360
sColl2–1(nM) n = 28; 462.04
(297.03;604.49)
n = 28; 556.76
(399.84;692.02)
n = 28; 653.36
(429.74;757.79)
n = 28; 599.67
(456.70;725.51)
n = 24; 557.73
(460.48;818.09)
n = 27; 598.44
(408.51;858.57)
Change from baseline n = 28; 37.03
(−45.30;140.52)
n = 28; 61.29
(−31.90;250.43)
n = 28; 106.88
(31.31;265.17)
n = 24; 145.72
(−40.33;201.72)
n = 27; 123.74
(−6.52;273.51)
P-value vs D0 0.162 0.018 0.001 0.066 0.005
sColl2-NO2 (pg/ml) n = 20; 335.13
(268.79;467.17)
n = 23; 271.58
(222.80;393.76)
n = 23; 283.65
(212.03;599.42)
n = 22; 317.89
(264.34;450.43)
n = 18; 491.21
(271.25;624.31)
n = 20; 485.38
(307.04;740.40)
Change from baseline n = 20; −34.88
(−65.31;62.77)
n = 18; −36.62
(−73.09;87.12)
n = 18; −9.71
(− 65.55;104.32)
n = 14; 44.37
(− 67.38;202.55)
n = 16; 76.89
(−55.92;334.31)
P-value vs D0 0.498 0.832 0.899 0.426 0.175
uCTX-II (ug/mmol creatinine) n = 24; 0.012
(0.008;0.014)
n = 25; 0.012
(0.009;0.015)
n = 23; 0.010
(0.008;0.016)
n = 26; 0.012
(0.009;0.014)
n = 23; 0.011
(0.007;0.015)
n = 23; 0.010
(0.008;0.014)
Change from baseline n = 23; 0.001
(−0.002;0.003)
n = 21; 0.001
(−0.003;0.001)
n = 23; 0.000
(− 0.003;0.003)
n = 21; 0.000
(− 0.002;0.003)
n = 22; − 0.001
(− 0.003;0.002)
P-value vs D0 0.357 0.626 0.791 0.987 0.420
sPIINP (ng/ml) n = 27; 590.14
(500.89; 740.87)
n = 24; 651.57
(529.91; 875.12)
n = 26; 697.9
(544.21; 858.85)
n = 27; 780.2
(572.88; 999.99)
n = 22; 865.69
(752.23;1075.72)
n = 24; 1002.69
(664.39;1263.72)
Change from baseline n = 23; 5.83
(−87.64;87.38)
n = 26; 57.68
(− 96.03;172.51)
n = 27; 90.35
(−23.12;298.16)
n = 22; 198.77
(144.54;368.52)
n = 24; 417.05
(115.26;529.05)
P-value vs D0 0.791 0.434 0.004 < 0.001 < 0.001
sColl2–1 (nM)/sPIINP (ng/ml) n = 27; 0.66
(0.49; 0.96)
n = 24; 0.69
(0.45; 0.93)
n = 26; 0.78
(0.60; 1.00)
n = 27; 0.76
(0.60; 0.94)
n = 22; 0.61
(0.54;0.82)
n = 24; 0.52
(0.44;0.62)
Change from baseline n = 23; 0.07
(−0.09; 0.24)
n = 26; 0.00
(− 0.08; 0.34)
n = 27; 0.04
(− 0.21; 0.20)
n = 22; − 0.04
(− 0.40; 0.12)
n = 24; − 0.12
(− 0.30; − 0.01)
P-value vs D0 0.465 0.258 0.665 0.306 0.022
uCTX-II (ng/mmol creatinine)/
sPIINP (ng/ml)
n = 23; 0.018
(0.010; 0.028)
n = 21; 0.025
(0.011; 0.029)
n = 22; 0.015
(0.010; 0.018)
n = 25; 0.016
(0.011; 0.024)
n = 22; 0.012
(0.008; 0.016)
n = 20; 0.011
(0.007; 0.019)
Change from baseline n = 18; −0.001
(− 0.004; 0.003)
n = 20; − 0.002
(− 0.007; 0.002)
n = 22; − 0.004
(− 0.008; 0.002)
n = 20; − 0.003
(− 0.011; − 0.001)
n = 19; −0.007
(− 0.013; − 0.002)
P-value vs D0 0.777 0.218 0.046 < 0.001 < 0.001
sCS-846 (ng/ml) n = 23; 140.14
(117.75;186.18)
n = 23; 127.73
(123.57;188.92)
n = 24; 131.47
(113.90;174.13)
n = 24; 156.04
(127.58;183.30)
n = 23; 161.33
(120.75;174.33)
n = 25; 164.94
(135.04;204.99)
Change from baseline n = 21; − 1.82
(− 17.50;5.25)
n = 21; −7.30
(−23.49;7.85)
n = 20; 13.64
(−5.99;20.73)
n = 19; 1.534
(− 15.11;29.84)
n = 21; 11.30
(−4.93;24.80)
P-value vs D0 0.352 0.212 0.231 0.651 0.143
sCOMP (ng/ml) n = 28; 802.85
(613.44;1050.03)
n = 28; 855.56
(607.44;1097.99)
n = 28; 746.93
(611.46;979.58)
n = 28; 751.8
(617.94;977.22)
n = 24; 770.23
(584.69;1014.59)
n = 27; 800.09
(613.54;1060.12)
AChange from baseline n = 28; 26.33
(−43.24;152.94)
n = 28; 5.75
(−107.05;107.18)
n = 28; − 10.06
(− 109.63;121.00)
n = 24; − 33.70
(− 113.39;103.32)
n = 27; 13.56
(− 133.86;109.46)
P-value vs D0 0.176 0.929 0.947 0.678 0.797
sMMP-3 (ng/ml) n = 28; 14.67
(11.89;21.58)
n = 28; 16.43
(12.14;23.93)
n = 28; 15.98
(13.92;22.67)
n = 28; 16.00
(12.23;22.15)
n = 24; 16.53
(12.9;23.0)
n = 27; 15.63
(11.56;24.06)
Change from baseline n = 28; 1.19
(−0.91;2.97)
n = 28; 1.94
(− 0.19;4.29)
n = 28; 0.91
(−2.52;3.48)
n = 24; 1.39
(− 0.92;2.7)
n = 27; 0.46
(−1.99;3.58)
P-value vs D0 0.282 0.006 0.348 0.071 0.511
sIL-6 (pg/ml) n = 28; 1.47
(1.10;2.00)
n = 27; 1.60
(1.22;2.35)
n = 27; 1.67
(1.28;2.42)
n = 28; 1.49
(1.11;2.47)
n = 23; 1.48
(1.13;2.23)
n = 27; 1.83
(0.97;2.86)
Change from baseline n = 27; 0.21
(−0.12;0.48)
n = 27; 0.03
(− 0.30;-0.61)
n = 28; − 0.004
(− 0.11;0.49)
n = 23; 0.21
(− 0.09;0.46)
n = 27; 0.33
(− 0.13;1.13)
P-value vs D0 0.030 0.481 0.348 0.108 0.017
sMPO (ng/ml) n = 27; 199.49
(140.46;264.05)
n = 28; 240.45
(134.93;308.59)
n = 28; 187.17
(142.02;336.18)
n = 28; 208.81
(114.126;285.47)
n = 22; 161.96
(82.81;241.45)
n = 24; 174.51
(93.23;216.50)
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mm). No change was observed in the other compart-
ments (Table 7).
Neutral, positive and negative curvature correspond to
a flat, convex, and concave surface respectively. Cartilage
curvature significantly decreased at D360 for 3 distinct
convex (positive curvature) surfaces: femur (− 0,001
mm− 1, p = 0.015), medial weight bearing femur (− 0,001
mm− 1, p = 0.027), lateral tibia (− 0,002 mm− 1, p = 0.02).
These results suggest a flattening of medial femur shape.
Pain and function
In comparison to baseline, VAS at rest and while walking
was significantly decreased at each time point (mean de-
crease from − 20.1 mm to − 29.9 mm and from − 25.5
mm to − 31.5 mm at rest and while walking respectively,
p < 0.001) (Fig. 3). Similarly, patient and investigator glo-
bal assessment of the disease activity scores were signifi-
cantly reduced at each time point compared to baseline
value (p < 0.001) (Fig. 3, Table 8).
KOOS global score and subscale significantly increased
overtime (mean improvement from 16.173 to 21.341 and
from 15.384 to 20.511 in pain sub-score and in activities
of daily living score respectively; p < 0.001 for all sub-
scales) (Fig. 4, Table 9). The ratio of OARSI-OMERACT
responders in the FAS population increased overtime.
This ratio was 48,9% at D180 and 70.7% at D360.
Patient’s satisfaction
At D30, patient satisfaction was good, with 43.5% of pa-
tients feeling better, 37% feeling a little better, 15.2% feel-
ing no change, 4.3% feeling little lower and none far
lower. Between D30 and D360, patient’s satisfaction
remained stable.
Correlations between imaging, clinical and biological
parameters
At baseline, the VAS walking pain were positively and
significantly correlated with cartilage volume (r = −
0.42779; p = 0.007) and thickness (r = − 0.38758; p =
0.015). VAS changes overtime (from baseline to D180 or
from baseline to D360) were not correlated with MRI
changes overtime.
At baseline, VAS walking pain was positively correlated
with sColl2–1NO2 levels (r = − 0.53617; p = 0.002), but
not with the other biomarkers. No significant correlation
was found between VAS walking pain and biomarkers at
follow-up time points.
Safety
Ninety-five (95) AEs were reported after the first treat-
ment cycle in 37 patients (80% of the SAS). Eleven pa-
tients (23.9%) presented an Adverse Device Reaction
(ADR). In total, 15 ADRs (16% of AE) have been re-
ported: difficulty to extend leg, redness of the patella,
knee pain after injection, knee swelling, injection site
pain, pain at injection, dizziness and knee swelling. Im-
portantly, only one AE led to treatment discontinuation
and only one led to patient withdrawal but were not re-
lated to the product. Eight (15.2% of the safety popula-
tion) SAEs have been recorded during the study.
Importantly, no SAE was linked to the study medication.
Discussion
This non-controlled prospective study provided a lot of
precious information on the evolution of biological, struc-
tural and clinical parameters after intra-articular injection
of HYMOVIS®. These results will be valuable for the design
of a randomized and controlled study aiming to demon-
strate the disease modifying effect of viscosupplementation.
We have investigated the evolution profile of biomarkers of
type II collagen metabolism. Coll2–1 and CTX-II are both
biomarkers of cartilage degradation [40–43] while PIIANP
is a biomarker of collagen synthesis [44]. Interestingly,
Table 4 levels (median (IQR)) of soluble biomarkers in the Per Protocol Population (Continued)
D0 D30 D90 D180 D210 D360
Change from baseline n = 27; 36.24
(−41.33;96.54)
n = 27; 30.40
(−48.99;84.18)
n = 27; 22.83
(−71.70;95.12)
n = 21; −16.46
(−62.60;39.60)
n = 23; − 4.74
(− 43.30;24.41)
P-value vs D0 0.160 0.237 0.481 0.317 0.555
Table 5 WORMS total score and by features (mean (SD)) in the
Full Analysis Set population
D0 D180 D360
WORMS total score 63.95 (27.78) 64.39 (27.71) 64.08 (28.03)
Change from baseline 0.38 (1.77) 0.96 (2.75)
p value 0.183 0.037
Cartilage 23.83 (11.27) 23.01 (11.13) 23.03 (11.45)
Change from baseline 0.18 (0.70) 0.45 (1.21)
p value 0.188 0.025
Cyst 2.73 (2.65) 2.83 (2.65) 2.90 (2.62)
Change from baseline 0.10 (0.30) 0.23 (0.63)
p value 0.125 0.047
Effusion 0.93 (0.69) 0.76 (0.54) 0.77 (0.54)
Change from baseline −0.17 (0.38) −0.15 (0.54)
p value 0.016 0.148
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Coll2–1 and PIIANP increased overtime while CTX-II
remained stable. As the ratio Coll2–1/PIIANP and
CTX-II/PIIANP decreased overtime, these biomarkers
variations can be interpreted as a positive effect of
the HYMOVIS® on type II collagen turnover. How-
ever, in the absence of a control group, we can not
exclude that these changes are simply the conse-
quence of changes in the cartilage matrix turnover
linked to natural disease evolution. The observation
that Coll2–1 increased while CTX-II remained stable
is surprising. This can be explained in two ways. First,
CTX-II and Coll2–1 epitopes are generated by differ-
ent mechanisms. CTX-II is a neoepitope located in
the C-terminal telopeptide and generated enzymati-
cally whereas Coll2–1 is a peptide located in triple
helix and released after denaturation of the collagen
[45]. Secondly, there is evidence that urinary level of
CTX-II is influenced by bone remodeling which is
not demonstrated for Coll2–1 [46, 47]. Therefore, we
can hypothesize that metabolic change induced by visco-
supplementation in a single joint is not sufficient to influ-
ence the urinary CTX-II level resulting from bone and
cartilage remodeling, while as demonstrated previously,
Coll2–1 is sensitive to changes occurring in one single joint
[42, 48].
To demonstrate the structure-modifying effect of vis-
cosupplementation, the EUROVISCO group recom-
mends a combination of imaging and biological outcome
measures [49]. A decrease of soluble biomarkers of
cartilage degradation over time does not prove the
chondroprotective effect of the treatment if this effect
is not complemented by the imaging examinations.
One strength of this study is that we have combined
MRI and biological markers. Based on the literature
review, a worsening of the MRI features was antici-
pated after 12 months follow-up [50]. In this study,
T2 relaxation time analysis revealed an improvement
of cartilage quality in total femur and in the lateral
weight bearing femur as well as in the patella as soon
as 6 months. WORMS effusion score, an indicator of
synovitis, also revealed an improvement after 6
months. Finally, cartilage volume and thickness
showed an increase in lateral weight bearing femur.
The improvement in cartilage T2 values and volume
in the lateral weight bearing femur can be interpreted
as a beneficial effect of HYMOVIS®. These changes in
Table 6 Mean T2 relaxation time and standard deviation of relaxation time for patella (median (IQR)) in the Full Analysis Set
population
Mean T2 relaxation time (ms) SD of relaxation time (ms)
Median (IQR) n = 38 p-value Median (IQR)n = 38 p-value
Whole Patella- whole layer D180 vs D0
D360 vs D0
2.822 (− 3.872; 8.996)




0.236 (− 9.654; 7.812)
0.480
0.960
Whole Patella- top layer D180 vs D0
D360 vs D0
4.446 (−6.977; 16.697)
4.937 (− 10.051; 21.672)
0.320
0.327
6.644 (− 21.994; 20.796)
1.413 (− 16.726; 28.354)
0.593
0.603
Whole Patella- middle layer D180 vs D0
D360 vs D0
1.236 (−2.881; 6.889)
0.125 (− 6.598; 7.365)
0.356
0.803
0.788 (− 4.667; 6.221)
− 0.333 (− 11.132; 13.976)
0.603
0.870
Whole Patella- bottom layer D180 vs D0
D360 vs D0
0.202 (− 3.239; 5.418)
− 0.228 (− 2.205; 5.368)
0.545
0.633
1.115 (− 2.416; 5.700)
0.408 (− 4.172; 6.304)
0.320
0.644
Medial trochlea - whole layer D180 vs D0
D360 vs D0
−2.354 (− 16.342; 4.102)
− 2.429 (− 12.540; 0.968)
0.061
0.019
−1.959 (− 8.472; 1.353)
− 0.818 (− 6.424; 1.126)
0.008
0.107
Medial trochlea - top layer D180 vs D0
D360 vs D0
−1.768 (− 8.476; 1.722)
− 1.777 (− 9.093; 2.549)
0.027
0.075
−1.774 (− 6.983; 1.804)
− 0.449 (− 5.186; 1.711)
0.023
0.229
Medial trochlea - middle layer D180 vs D0
D360 vs D0
1.606 (− 14.664; 2.549)
− 1.45 (− 10.896; 0.991)
0.032
0.024
−2.074 (− 9.846; 2.389)
− 0.796 (− 7.151; 0.737)
0.011
0.033
Medial trochlea- bottom layer D180 vs D0
D360 vs D0
−2.303 (− 21.865; 7.574)
− 1.852 (− 16.764; 0.791)
0.16
0.023
−2.703 (− 13.902; 2.017)
− 1.574 (− 8.096; 2.390)
0.006
0.124
Lateral trochlea - whole layer D180 vs D0
D360 vs D0
− 2.167 (− 10.398; 0.720)
− 2.107 (− 11.110; 0.938)
0.001
0.006
− 0.804 (− 6.646; 2.799)
− 0.508 (− 3.996; 0.839)
0.110
0.117
Lateral trochlea - top layer D180 vs D0
D360 vs D0
− 0.410 (− 8.520; 4.261)
0.169 (− 5.191; 7.014)
0.623
0.848
1.069 (− 7.704; 10.070)
0.670 (− 3.756; 8.526)
0.972
0.387
Lateral trochlea - middle layer D180 vs D0
D360 vs D0
−3.663 (− 11.111; 0.482)
− 2.380 (− 10.532; 0.399)
0.001
0.001
− 1.473 (− 9.228; 0.898)
− 1.547 (− 7.190; − 0.374)
0.009
0.003
Lateral trochlea - bottom layer D180 vs D0
D360 vs D0
−2.538 (− 26.748; 0.497)
− 2.677 (− 20.622; 0.621)
0.001
0.002
−1.188 (− 8.698; 0.999)
− 2.245 (− 9.955; 1.961)
0.005
0.012
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cartilage structure and volume could be the result of
type II collagen turnover increase as suggested by
collagen-derived biomarkers. However, in this study,
no significant correlation has been found between sol-
uble biomarkers levels at baseline and the severity or
changes of MRI features. Therefore, this explanation
remains hypothetical.
A significant decrease of knee pain and an improve-
ment of joint function was observed. Similarly, a sig-
nificant improvement of patient and investigator
Table 7 Mean T2 relaxation time and standard deviation of relaxation time for femur (median (IQR)) in the Full Analysis Set
population






Whole Femur- whole layer D180 vs D0
D360 vs D0
−0.537 (−10.658; 2.368)




− 0.588 (− 4.128; 1.634)
0.160
0.279
Whole Femur- top layer D180 vs D0
D360 vs D0
− 1.589 (−6.682; 2.216)
− 1.678 (− 6.797; 3.763)
0.080
0.131
− 0.697 (− 7.715; 5.048)
1.159 (− 5.690; 6.124)
0.574
0.545
Whole Femur- middle layer D180 vs D0
D360 vs D0
−0.596 (10.378; 1.938)
− 1.249 (− 10.187; 0.967)
0.030
0.008
−1.524 (− 5.920; 1.637)
− 0.305 (− 5.309; 1.955)
0.86
0.174
Whole Femur- bottom layer D180 vs D0
D360 vs D0
−0.259 (− 10.454; 3.226)
− 2.051 (− 10.495; 1.684)
0.094
0.009
−0.944 (− 8.002; 1.725)
− 0.402 (− 8.032; 1.057)
0.027
0.055
Medial weight bearing femur- whole layer D180 vs D0
D360 vs D0
0.318 (− 14.381; 3.036)
− 1.680 (− 13.240; 2.583)
0.198
0.147
−1.320 (− 6.054; 2.027)
− 0.585 (− 5.550; 1.085)
0.059
0.124
Medial weight bearing femur- top layer D180 vs D0
D360 vs D0
−1.119 (− 8.54; 3.575)




− 1.741 (− 3.532; 10.667)
0.782
0.717
Medial weight bearing femur- middle layer D180 vs D0
D360 vs D0
0.115 (− 12.221; 2.005)
− 1.725 (− 8.003; 0.934)
0.086
0.057
−1.335 (− 8.136; 1.699)
− 1.718 (− 6.450; 0.685)
0.037
0.050
Medial weight bearing femur- bottom layer D180 vs D0
D360 vs D0
−0.261 (− 13.971; 5.085)
− 2.727 (− 10.766; 3.163)
0.254
0.053
−1.506 (− 11.723; 1.387)
− 2.298 (− 8.391; 0.853)
0.010
0.012
Lateral weight bearing femur- whole layer D180 vs D0
D360 vs D0
−3.129 (− 8.423; 1.453)
− 1.748 (− 8.187; 2.160)
0.011
0.032
0.179 (− 3.713; 2.078)
− 0.123 (− 3.475; 2.057)
0.613
0.613
Lateral weight bearing femur- top layer D180 vs D0
D360 vs D0
0.580 (−7.286; 4.058)
− 0.628 (− 6.597; 3.953)
0.664
0.364
−0.375 (− 11.374; 5.426)
0.897 (− 5.299; 6.409)
0.412
0.792
Lateral weight bearing femur- middle layer D180 vs D0
D360 vs D0
−1.075 (− 7.777; 1.477)
− 1.264 (− 9.870; 1.896)
0.005
0.045
0.183 (− 3.536; 1.522)
− 0.589 (− 3.179; 1.625)
0.395
0.349
Lateral weight bearing femur- bottom layer D180 vs D0
D360 vs D0
−1.599 (− 12.514; 2.41)
− 2.164 (− 10.944; 3.286)
0.015
0.100
−1.053 (− 5.959; 0.667)
− 0.699 (− 6.740; 1.931)
0.005
0.110
Fig. 3 Time evolution of pain at rest, at walking, and patients and investigators global assessment. VAS = Visual Analog scale; PGADA = Patient
Global Assessment of Disease Activity; IGADA = Investigator Global Assessment of Disease Activity
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global assessement was observed. These improve-
ments are confirmed by the number of responders to
treatment which increases over time. However, in the
absence of control group, the interpretation of these
improvements may be less credible since placebo is
known to be effective at relieving pain and at improv-
ing function and stiffness [39, 51]. None of the bio-
markers were enable to discriminate between OARSI-
OMERACT non-responders and responders to treat-
ments. This is probably due to the small sample size.
HYMOVIS® shows a good safety profile with no
SAE related to the product. Remarkably, less than
15% of patients had definite product related reaction
the marjority being pain and swelling at site injection
and only one led to patient withdrawal. We can con-
clude that the product is well tolerated.
Conclusion
This prospective study indicates that HYMOVIS®, a well-
tolerated intra-articular treatment, significantly enhanced
type II collagen turnover as suggested by the increase in
Coll2–1 and PIIANP levels and cartilage volume observed
by MRI in lateral knee compartment only. Importantly,
this study highlighted the potential symptomatic benefit of
HYMOVIS® on pain and function. Altogether, theses data
suggest that HYMOVIS® could have a protective effect on
cartilage and provides critical information for the design
of a larger phase III clinical trial.
Table 8 VAS changes from baseline (mean (SD)) in the Full Analysis Set Population
VAS (mm) D30 vs D0 D90 vs D0 D180 vs D0 D210 vs D0 D360 vsD0










P-value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001










P-value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001










P-value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001










P-value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Fig. 4 Time evolution of Knee Injury and Osteoarthritis Outcome (KOOS) global score and subscores
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